Targeted mRNA Platforms Target Autoimmune Condition Management

 ·  1 min read

Clinical trials evaluating modified messenger RNA therapies for autoimmune diseases have advanced to Phase II trials, demonstrating precise modulation of autoreactive T-cells without broad immune suppression.

Clinical Outcomes and Delivery Systems
Nanoparticle delivery systems engineered to target liver sinusoidal endothelial cells have shown high specificity in early trials. Researchers report a statistically significant reduction in inflammatory biomarkers without systemic adverse effects.